sulfamethoxazole brands

31 registered brands containing sulfamethoxazole in Tanzania.

sulfamethoxazole

PubChem CID 5329

Molecular formula: C10H11N3O3S

Sulfamethoxazole is a sulfonamide that inhibits bacterial dihydrofolic acid synthesis due to its structural similarity to an endogenous substrate, para-aminobenzoic acid (PABA). Most bacteria meet their need for folic acid by synthesizing it from PABA, as opposed to Animalia that require exogenous folic acid sources. Sulfamethoxazole competitively inhibits dihydropteroate synthase, the enzyme responsible for bacterial conversion of PABA to dihydrofolic acid. Inhibition of this pathway prevents the synthesis of tetrahydrofolate and, ultimately, the synthesis of bacterial purines and DNA, resulting in a bacteriostatic effect. Sulfonamides are usually bacteriostatic in action. Sulfonamides interfere with the utilization of p-aminobenzoic acid (PABA) in the biosynthesis of tetrahydrofolic acid (the reduced form of folic acid) cofactors in susceptible bacteria. Sulfonamides are structural analogs of PABA and appear to interfere with PABA utilization by competitively inhibiting the enzyme dihydropteroate synthase, which catalyzes the formation of dihydropteroic acid (a precursor of tetrahydrofolic acid) from PABA and pteridine; however, other mechanism(s) affecting the biosynthetic pathway also may be involved. Compounds such as pyrimethamine and trimethoprim, which block later stages in the synthesis of folic acid, act synergistically with sulfonamides. Only microorganisms that synthesize their own folic acid are inhibited by sulfonamides; animal cells and bacteria which are capable of utilizing folic acid precursors or preformed folic acid are not affected by these drugs. The antibacterial activity of the sulfonamides is reportedly decreased in the presence of blood or purulent body exudates. /Sulfonamides/ /Sulfonamides inhibit bacterial growth by preventing para-aminobenzoic acid (PABA) from being incorporated/ into dihydropteroic acid, the immediate precursor of folic acid. Sensitive microorganisms are those that must synthesize their own folic acid; bacteria that can utilize preformed folate are not affected. Bacteriostasis induced by sulfonamides is counteracted by PABA competitively. Sulfonamides do not affect mammalian cells by this mechanism, since they require preformed folic acid and cannot synthesize it. /Sulfonamides/ Sulfonamides are broad-spectrum, bacteriostatic anti-infectives. They are structural analogs of para-aminobenzoic acid and competively inhibit a bacterial enzyme, dihydropteroate synthetase, that is responsible for incorporation of para-aminobenzoic acid into dihydrofolic acid. This blocks the synthesis of dihydrofolic acid and decreases the amount of metabolically active tetrahydrofolic acid, a cofactor for the synthesis of purines, thymidine, and DNA. /Sulfonamides/ The hydroxylamine and nitroso metabolites formed by N4-oxidation of sulfonamides are thought to be involved in the pathogenesis of idiosyncratic reactions to this class of drugs. Idiosyncratic reactions to sulfonamides are characterized by multisystemic toxicity, including hepatitis, nephritis, dermatitis, and blood dyscrasias (aplastic anemia, agranulocytosis). Previously it has been shown that cytochrome p-450 in the liver metabolizes sulfamethoxazole to its hydroxylamine metabolite. In this paper the N4-oxidation of sulfamethoxazole by activated monocytes and neutrophils (human and canine) to form sulfamethoxazole hydroxylamine and nitrosulfamethoxazole is reported. The presumed nitroso intermediate was not detected. Purified myeloperoxidase and prostaglandin H synthase were also capable of mediating the oxidation of sulfamethoxazole. The present studies suggest that myeloperoxidase is responsible for the observed oxidation by phagocytic cells. Oxidation by neutrophils may play a role in agranulocytosis, and oxidation by monocytes may facilitate antigen presentation. Extrahepatic bioactivation of sulfonamides by peroxidases in phagocytic cells and other tissues may be important in determining the range of adverse reactions to sulfonamides

Source: PubChem (NCBI) ยท compound 5329

Product Manufacturer Status Country
Alprim
Tablets
Elys Chemical Industries Registered/Compliant Tanzania
Alprim
Suspension, Oral
Elys Chemical Industries Registered/Compliant Tanzania
Betrim 480
Tablets
Milan Laboratories Registered/Compliant Tanzania
Betrim Forte
Tablets
Milan Laboratories Registered/Compliant Tanzania
BIOSOL WDP
Powder, Oral
Vetcare Kenya Registered/Compliant Tanzania
Biotrim
Suspension, Oral
Biodeal Laboratories Registered/Compliant Tanzania
Bronquidiazina CR
Oral Suspension
Faes Farma. S.a Registered/Compliant Tanzania
Bronquidiazina CR Suspension
Oral Suspension
Faes Farma Registered/Compliant Tanzania
Co Trimoxazole
Tablets
Medopharm Registered/Compliant Tanzania
Cosatrim
Tablets
Cosmos Registered/Compliant Tanzania
Cotrikant 480
Tablets
S Kant Healthcare Registered/Compliant Tanzania
Cotrikant 960
Tablets
S Kant Healthcare Limited Registered/Compliant Tanzania
COTRIMAX-KP 480 TABS
Tablets
- Registered/Compliant Tanzania
COTRIMAX-KP SUSPENSION
Suspension
Katwaza Pharmaceuticals Registered/Compliant Tanzania
Cotrimol 400/80
Uncoated Tablets
Ipca Laboratories Registered/Compliant Tanzania
Cotrimol 800/160
Uncoated Tablets
Ipca Laboratories Registered/Compliant Tanzania
Cotrivet
Powder
Medisel Registered/Compliant Tanzania
Isoniazid/Pyridoxine Hydrochloride/ Sulfamethoxazole/Trimethoprim tablets 300 mg/25 mg/800 mg/160 mg
Film Coated Tablet
Mylan Laboratories Registered/Compliant Tanzania
Lecotrim
Tablets
Laboratory & Allied Registered/Compliant Tanzania
Lecotrim
Suspension, Oral
Laboratory & Allied Registered/Compliant Tanzania
Oriprim
Tablets
Zydus Lifesciences Registered/Compliant Tanzania
Prinatrim
Suspension, Oral
Prince Pharmaceuticals Registered/Compliant Tanzania
Q-TIB
Tablets
Quality Chemical Industries Registered/Compliant Tanzania
SEPTRIMAX 480
Oral tablet
Scott-Edil Pharmacia Registered/Compliant Tanzania
Shetrim
Tablets
Shelys Pharmaceuticals Registered/Compliant Tanzania
Shetrim
Suspension, Oral
Shelys Pharmaceuticals Ltd Registered/Compliant Tanzania
SULPHATRIM
Oral tablet
Lincoln Pharmaceuticals Registered/Compliant Tanzania
SULPHATRIM
Suspension, Oral
Lincoln Pharmaceuticals Registered/Compliant Tanzania
Unitrim
Tablets
Regal Pharmaceuticals Registered/Compliant Tanzania
Unitrim
Suspension, Oral
Regal Pharmaceuticals Registered/Compliant Tanzania
Zentrim
Tablets
Zenufa Laboratories Registered/Compliant Tanzania